Business Description
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.35 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.61 | |||||
Interest Coverage | 4.1 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.12 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.6 | |||||
3-Year EBITDA Growth Rate | 25.7 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year Book Growth Rate | 20.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.89 | |||||
Quick Ratio | 0.57 | |||||
Days Inventory | 204.31 | |||||
Days Sales Outstanding | 53.85 | |||||
Days Payable | 127.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.9 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 69.65 | |||||
Operating Margin % | -25.83 | |||||
Net Margin % | -27.7 | |||||
FCF Margin % | 37.78 | |||||
ROE % | -118.54 | |||||
ROA % | -29.14 | |||||
ROIC % | -13.13 | |||||
ROC (Joel Greenblatt) % | -159.02 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 101.85 | |||||
PS Ratio | 4.09 | |||||
PB Ratio | 9.01 | |||||
Price-to-Tangible-Book | 15.3 | |||||
Price-to-Free-Cash-Flow | 35.21 | |||||
Price-to-Operating-Cash-Flow | 23.8 | |||||
EV-to-EBIT | 17.86 | |||||
EV-to-EBITDA | 14.22 | |||||
EV-to-Revenue | 4.31 | |||||
Price-to-Projected-FCF | 11.25 | |||||
Price-to-Median-PS-Value | 1.63 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.05 | |||||
Price-to-Graham-Number | 5.31 | |||||
Earnings Yield (Greenblatt) % | 5.6 | |||||
Forward Rate of Return (Yacktman) % | 23.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ranbaxy Laboratories Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 535.406 | ||
EPS (TTM) ($) | 0.185 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 0 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 4.74 - 11.26 | ||
Shares Outstanding (Mil) | 413.56 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ranbaxy Laboratories Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ranbaxy Laboratories Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Ranbaxy Laboratories Ltd Frequently Asked Questions
What is Ranbaxy Laboratories Ltd(LSE:RBXD)'s stock price today?
When is next earnings date of Ranbaxy Laboratories Ltd(LSE:RBXD)?
Does Ranbaxy Laboratories Ltd(LSE:RBXD) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |